

Laurence Zitvogel

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7945198/laurence-zitvogel-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

408
papers

72,567
citations

116
h-index

265
g-index

452
ext. papers

87,558
ext. citations

13.7
avg, IF

7.95
L-index

#	Paper	IF	Citations
408	Immunogenic cell stress and death.. <i>Nature Immunology</i> , 2022 ,	19.1	36
407	Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer.. <i>Nature Medicine</i> , 2022 ,	50.5	23
406	Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma.. <i>Nature Medicine</i> , 2022 ,	50.5	14
405	Modulation of cancer immunotherapy by dietary fibers and over-the-counter probiotics.. <i>Cell Metabolism</i> , 2022 , 34, 350-352	24.6	0
404	Cross-reactivity between microbial and tumor antigens.. <i>Current Opinion in Immunology</i> , 2022 , 75, 102174.8	17.8	0
403	Targeting the gut and tumor microbiota in cancer.. <i>Nature Medicine</i> , 2022 , 28, 690-703	50.5	15
402	Immunodynamics of explanted human tumors for immuno-oncology. <i>EMBO Molecular Medicine</i> , 2021 , 13, e12850	12	2
401	Impact of the ileal microbiota on colon cancer. <i>Seminars in Cancer Biology</i> , 2021 ,	12.7	2
400	The microbiome and human cancer. <i>Science</i> , 2021 , 371,	33.3	96
399	Oral administration of elevates systemic antiaging and anticancer metabolites. <i>Aging</i> , 2021 , 13, 6375-6405	9.5	27
398	Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers. <i>Cell Death and Disease</i> , 2021 , 12, 258	9.8	37
397	Subversion of calreticulin exposure as a strategy of immune escape. <i>Cancer Cell</i> , 2021 , 39, 449-451	24.3	4
396	Beneficial autoimmunity improves cancer prognosis. <i>Nature Reviews Clinical Oncology</i> , 2021 , 18, 591-602	19.4	21
395	Bortezomib Induces Immunogenic Cell Death in Multiple Myeloma. <i>Blood Cancer Discovery</i> , 2021 , 2, 405-407	407	0
394	Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment. <i>Cell Death and Differentiation</i> , 2021 , 28, 2778-2796	12.7	13
393	Fecal microbiota transplantation: can it circumvent resistance to PD-1 blockade in melanoma?. <i>Signal Transduction and Targeted Therapy</i> , 2021 , 6, 178	21	1
392	Multifaceted modes of action of the anticancer probiotic <i>Enterococcus hirae</i> . <i>Cell Death and Differentiation</i> , 2021 , 28, 2276-2295	12.7	9

391	Effects of acyl-coenzyme A binding protein (ACBP)/diazepam-binding inhibitor (DBI) on body mass index. <i>Cell Death and Disease</i> , 2021 , 12, 599	9.8	5
390	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. <i>Nature Medicine</i> , 2021 , 27, 1432-1441	50.5	57
389	Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis. <i>Cell Death and Differentiation</i> , 2021 , 28, 3297-3315	12.7	7
388	A TLR3 Ligand Reestablishes Chemotherapeutic Responses in the Context of FPR1 Deficiency. <i>Cancer Discovery</i> , 2021 , 11, 408-423	24.4	12
387	Ileal immune tonus is a prognosis marker of proximal colon cancer in mice and patients. <i>Cell Death and Differentiation</i> , 2021 , 28, 1532-1547	12.7	2
386	Immunomodulation by targeted anticancer agents. <i>Cancer Cell</i> , 2021 , 39, 310-345	24.3	44
385	Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade. <i>JCI Insight</i> , 2021 , 6,	9.9	45
384	Lower Airway Dysbiosis Exacerbates Lung Cancer. <i>Cancer Discovery</i> , 2021 , 11, 224-226	24.4	4
383	Immune checkpoint inhibitors. <i>Journal of Experimental Medicine</i> , 2021 , 218,	16.6	9
382	Microbiota-Centered Interventions: The Next Breakthrough in Immuno-Oncology?. <i>Cancer Discovery</i> , 2021 , 11, 2396-2412	24.4	14
381	Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease. <i>Immunity</i> , 2021 , 54, 1883-1900.e5	32.3	30
380	Autoimmunity affecting the biliary tract fuels the immunosurveillance of cholangiocarcinoma. <i>Journal of Experimental Medicine</i> , 2021 , 218,	16.6	4
379	Commensals shape the immune system. <i>Nature Reviews Immunology</i> , 2021 , 21, 615	36.5	
378	The Porto European Cancer Research Summit 2021. <i>Molecular Oncology</i> , 2021 , 15, 2507-2543	7.9	1
377	A genotype-phenotype screening system using conditionally immortalized immature dendritic cells. <i>STAR Protocols</i> , 2021 , 2, 100732	1.4	1
376	Harnessing the microbiome to restore immunotherapy response.. <i>Nature Cancer</i> , 2021 , 2, 1301-1304	15.4	1
375	Cancer induces a stress ileopathy depending on B-adrenergic receptors and promoting dysbiosis that contribute to carcinogenesis.. <i>Cancer Discovery</i> , 2021 ,	24.4	4
374	CD4 T Cells at the Center of Inflammaging. <i>Cell Metabolism</i> , 2020 , 32, 4-5	24.6	4

373	Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients. <i>European Urology</i> , 2020 , 78, 195-206	10.2	67
372	Seeking Cellular Fitness and Immune Evasion: Autophagy in Pancreatic Carcinoma. <i>Cancer Cell</i> , 2020 , 37, 759-760	24.3	4
371	Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapy. <i>OncolImmunology</i> , 2020 , 9, 1774298	7.2	13
370	Trial watch: TLR3 agonists in cancer therapy. <i>OncolImmunology</i> , 2020 , 9, 1771143	7.2	23
369	Combination treatments with hydroxychloroquine and azithromycin are compatible with the therapeutic induction of anticancer immune responses. <i>OncolImmunology</i> , 2020 , 9, 1789284	7.2	3
368	Comedications influence immune infiltration and pathological response to neoadjuvant chemotherapy in breast cancer. <i>OncolImmunology</i> , 2020 , 9, 1677427	7.2	5
367	Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology. <i>OncolImmunology</i> , 2020 , 9, 1703449	7.2	81
366	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death 2020 , 8,		233
365	Gut microbiome to predict efficacy and immune-related toxicities in patients with advanced non-small cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3095-3095	2.2	2
364	Inhibition of transcription by dactinomycin reveals a new characteristic of immunogenic cell stress. <i>EMBO Molecular Medicine</i> , 2020 , 12, e11622	12	31
363	Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer. <i>Nature Medicine</i> , 2020 , 26, 919-931	50.5	55
362	Immunosuppression by Mutated Calreticulin Released from Malignant Cells. <i>Molecular Cell</i> , 2020 , 77, 748-760.e9	17.6	45
361	The immuno-oncological challenge of COVID-19.. <i>Nature Cancer</i> , 2020 , 1, 946-964	15.4	52
360	Can we harness the microbiota to enhance the efficacy of cancer immunotherapy?. <i>Nature Reviews Immunology</i> , 2020 , 20, 522-528	36.5	26
359	Trial watch: STING agonists in cancer therapy. <i>OncolImmunology</i> , 2020 , 9, 1777624	7.2	61
358	Trial watch: IDO inhibitors in cancer therapy. <i>OncolImmunology</i> , 2020 , 9, 1777625	7.2	45
357	Turning tolerogenic into immunogenic ileal cell death through ileal microbiota: the key to unlock the mystery of colon cancer immunoscore?. <i>OncolImmunology</i> , 2020 , 9, 1778834	7.2	1
356	Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2020 , 17, 725-741	19.4	223

355	The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non-Small Cell Lung Cancer. <i>Cancer Immunology Research</i> , 2020 , 8, 1243-1250	12.5	53
354	Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. <i>Nature Communications</i> , 2020 , 11, 3819	17.4	41
353	Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19. <i>Cell</i> , 2020 , 182, 1401-1418.e18	56.2	359
352	Pegylated Engineered IL2 plus Anti-PD-1 Monoclonal Antibody: The Nectar Comes from the Combination. <i>Cancer Discovery</i> , 2020 , 10, 1097-1099	24.4	2
351	Inosine: novel microbiota-derived immunostimulatory metabolite. <i>Cell Research</i> , 2020 , 30, 942-943	24.7	8
350	Elucidating the gut microbiota composition and the bioactivity of immunostimulatory commensals for the optimization of immune checkpoint inhibitors. <i>OncImmunology</i> , 2020 , 9, 1794423	7.2	3
349	Immune responses during COVID-19 infection. <i>OncImmunology</i> , 2020 , 9, 1807836	7.2	49
348	Antibiotics impair immunotherapy for urothelial cancer. <i>Nature Reviews Urology</i> , 2020 , 17, 605-606	5.5	3
347	On-target versus off-target effects of drugs inhibiting the replication of SARS-CoV-2. <i>Cell Death and Disease</i> , 2020 , 11, 656	9.8	24
346	Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage. <i>Science</i> , 2020 , 369, 936-942	33.3	74
345	Resolving the Paradox of Colon Cancer Through the Integration of Genetics, Immunology, and the Microbiota. <i>Frontiers in Immunology</i> , 2020 , 11, 600886	8.4	11
344	Oncolysis without viruses - inducing systemic anticancer immune responses with local therapies. <i>Nature Reviews Clinical Oncology</i> , 2020 , 17, 49-64	19.4	41
343	Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. <i>Cell Research</i> , 2019 , 29, 846-861	24.7	91
342	Stress-glucocorticoid-TSC22D3 axis compromises therapy-induced antitumor immunity. <i>Nature Medicine</i> , 2019 , 25, 1428-1441	50.5	87
341	Leptin-Producing Oncolytic Virus Makes Tumor-Infiltrating T Cells Fit, Not Fat. <i>Immunity</i> , 2019 , 51, 423-435	25.3	3
340	A synergistic triad of chemotherapy, immune checkpoint inhibitors, and caloric restriction mimetics eradicates tumors in mice. <i>OncImmunology</i> , 2019 , 8, e1657375	7.2	38
339	Upregulation of intratumoral HLA class I and peritumoral Mx1 in ulcerated melanomas. <i>OncImmunology</i> , 2019 , 8, e1660121	7.2	2
338	Interferon- γ induces cancer cell ferroptosis. <i>Cell Research</i> , 2019 , 29, 692-693	24.7	10

337	Tumor lysis with LTX-401 creates anticancer immunity. <i>Onc Immunology</i> , 2019 , 8, 1594555	7.2	14
336	A fluorescent biosensor-based platform for the discovery of immunogenic cancer cell death inducers. <i>Onc Immunology</i> , 2019 , 8, 1606665	7.2	6
335	Trial watch: dietary interventions for cancer therapy. <i>Onc Immunology</i> , 2019 , 8, 1591878	7.2	28
334	Crizotinib-induced immunogenic cell death in non-small cell lung cancer. <i>Nature Communications</i> , 2019 , 10, 1486	17.4	95
333	Contribution of annexin A1 to anticancer immunosurveillance. <i>Onc Immunology</i> , 2019 , 8, e1647760	7.2	10
332	Trial watch: dendritic cell vaccination for cancer immunotherapy. <i>Onc Immunology</i> , 2019 , 8, e1638212	7.2	71
331	Immunostimulatory gut bacteria. <i>Science</i> , 2019 , 366, 1077-1078	33.3	12
330	Anticancer effects of anti-CD47 immunotherapy. <i>Onc Immunology</i> , 2019 , 8, 1550619	7.2	19
329	Systemic autophagy in the therapeutic response to anthracycline-based chemotherapy. <i>Onc Immunology</i> , 2019 , 8, e1498285	7.2	14
328	The intimate relationship between gut microbiota and cancer immunotherapy. <i>Gut Microbes</i> , 2019 , 10, 424-428	8.8	54
327	CD16NKG2A Natural Killer Cells Infiltrate Breast Cancer-Draining Lymph Nodes. <i>Cancer Immunology Research</i> , 2019 , 7, 208-218	12.5	19
326	The impact of the intestinal microbiota in therapeutic responses against cancer. <i>Comptes Rendus - Biologies</i> , 2018 , 341, 284-289	1.4	47
325	The gut microbiota influences anticancer immunosurveillance and general health. <i>Nature Reviews Clinical Oncology</i> , 2018 , 15, 382-396	19.4	222
324	Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy. <i>Onc Immunology</i> , 2018 , 7, e1433982	7.2	23
323	Cancer immunotherapy in 2017: The breakthrough of the microbiota. <i>Nature Reviews Immunology</i> , 2018 , 18, 87-88	36.5	77
322	eIF2 γ phosphorylation is pathognomonic for immunogenic cell death. <i>Cell Death and Differentiation</i> , 2018 , 25, 1375-1393	12.7	87
321	Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. <i>Cell Death and Differentiation</i> , 2018 , 25, 486-541	12.7	2160
320	The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1. <i>Onc Immunology</i> , 2018 , 7, e1434468	7.2	34

319	The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies. <i>Science</i> , 2018 , 359, 1366-1370	33.3	341
318	Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. <i>Science</i> , 2018 , 359, 91-97	33.3	2203
317	TNFR2/BIRC3-TRAF1 signaling pathway as a novel NK cell immune checkpoint in cancer. <i>Oncolmunology</i> , 2018 , 7, e1386826	7.2	16
316	Reply to "Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma" <i>Nature Communications</i> , 2018 , 9, 2922	17.4	3
315	Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors. <i>Oncolmunology</i> , 2018 , 7, e1503032	7.2	50
314	Anticorps monoclonaux en oncologie : déclencher une réponse immunitaire en plus de la réduction tumorale spécifique.. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2018 , 202, 707-735	0.1	
313	A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment. <i>Cancer Research</i> , 2018 , 78, 1003-1016	10.1	159
312	Targeting Chemokines and Chemokine Receptors in Melanoma and Other Cancers. <i>Frontiers in Immunology</i> , 2018 , 9, 2480	8.4	35
311	Oncolysis with DTT-205 and DTT-304 generates immunological memory in cured animals. <i>Cell Death and Disease</i> , 2018 , 9, 1086	9.8	13
310	Trial Watch: Toll-like receptor agonists in cancer immunotherapy. <i>Oncolmunology</i> , 2018 , 7, e1526250	7.2	109
309	Trial watch: Peptide-based vaccines in anticancer therapy. <i>Oncolmunology</i> , 2018 , 7, e1511506	7.2	90
308	TumGrowth: An open-access web tool for the statistical analysis of tumor growth curves. <i>Oncolmunology</i> , 2018 , 7, e1462431	7.2	55
307	Impact of chemotactic factors and receptors on the cancer immune infiltrate: a bioinformatics study revealing homogeneity and heterogeneity among patient cohorts. <i>Oncolmunology</i> , 2018 , 7, e1484980	7.2	19
306	Enhancing the clinical coverage and anticancer efficacy of immune checkpoint blockade through manipulation of the gut microbiota. <i>Oncolmunology</i> , 2017 , 6, e1132137	7.2	28
305	NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients. <i>Oncolmunology</i> , 2017 , 6, e1137418	7.2	37
304	Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer. <i>Oncolmunology</i> , 2017 , 6, e1163456	7.2	22
303	Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma. <i>Oncolmunology</i> , 2017 , 6, e1299303	7.2	14
302	Pro-necrotic molecules impact local immunosurveillance in human breast cancer. <i>Oncolmunology</i> , 2017 , 6, e1299302	7.2	50

301	Trial watch: Dendritic cell-based anticancer immunotherapy. <i>OncolImmunology</i> , 2017 , 6, e1328341	7.2	70
300	Anticancer effects of the microbiome and its products. <i>Nature Reviews Microbiology</i> , 2017 , 15, 465-478	22.2	257
299	Shifting the Balance of Activating and Inhibitory Natural Killer Receptor Ligands on Melanoma Lines with Vemurafenib. <i>Cancer Immunology Research</i> , 2017 , 5, 582-593	12.5	14
298	Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN- γ Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy. <i>Cancer Research</i> , 2017 , 77, 4146-4157	10.1	79
297	Reply: The complement system is also important in immunogenic cell death. <i>Nature Reviews Immunology</i> , 2017 , 17, 143	36.5	5
296	Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics. <i>OncolImmunology</i> , 2017 , 6, e1386829	7.2	143
295	Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance. <i>Immunological Reviews</i> , 2017 , 280, 165-174	11.3	52
294	Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications. <i>OncolImmunology</i> , 2017 , 6, e1371896	7.2	33
293	Trial watch: Immune checkpoint blockers for cancer therapy. <i>OncolImmunology</i> , 2017 , 6, e1373237	7.2	53
292	Nutrition, inflammation and cancer. <i>Nature Immunology</i> , 2017 , 18, 843-850	19.1	197
291	The immune contexture in cancer prognosis and treatment. <i>Nature Reviews Clinical Oncology</i> , 2017 , 14, 717-734	19.4	935
290	Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells. <i>Nature Immunology</i> , 2017 , 18, 1004-1015	19.1	330
289	Trial Watch: Adoptively transferred cells for anticancer immunotherapy. <i>OncolImmunology</i> , 2017 , 6, e1363139	7.2	37
288	Trial watch: DNA-based vaccines for oncological indications. <i>OncolImmunology</i> , 2017 , 6, e1398878	7.2	22
287	Identification of pharmacological agents that induce HMGB1 release. <i>Scientific Reports</i> , 2017 , 7, 14915	4.9	25
286	Immunogenic cell death in cancer and infectious disease. <i>Nature Reviews Immunology</i> , 2017 , 17, 97-111	36.5	1257
285	Impact of antibiotics on outcome in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 462-462	2.2	26
284	Improvement of immunogenic chemotherapy by STAT3 inhibition. <i>OncolImmunology</i> , 2016 , 5, e1078061	7.2	9

283	Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy. <i>OncolImmunology</i> , 2016 , 5, e1088631	7.2	81
282	Differences in the composition of the immune infiltrate in breast cancer, colorectal carcinoma, melanoma and non-small cell lung cancer: A microarray-based meta-analysis. <i>OncolImmunology</i> , 2016 , 5, e1067746	7.2	10
281	Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. <i>OncolImmunology</i> , 2016 , 5, e1071008	7.2	367
280	Fine-Tuning Cancer Immunotherapy: Optimizing the Gut Microbiome. <i>Cancer Research</i> , 2016 , 76, 4602-7	10.1	69
279	The ratio of CD8/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma. <i>OncolImmunology</i> , 2016 , 5, e1218106	7.2	39
278	Trial Watch: Immunotherapy plus radiation therapy for oncological indications. <i>OncolImmunology</i> , 2016 , 5, e1214790	7.2	51
277	Immunological Mechanisms Underneath the Efficacy of Cancer Therapy. <i>Cancer Immunology Research</i> , 2016 , 4, 895-902	12.5	93
276	Impact of Pattern Recognition Receptors on the Prognosis of Breast Cancer Patients Undergoing Adjuvant Chemotherapy. <i>Cancer Research</i> , 2016 , 76, 3122-6	10.1	42
275	Calreticulin expression: Interaction with the immune infiltrate and impact on survival in patients with ovarian and non-small cell lung cancer. <i>OncolImmunology</i> , 2016 , 5, e1177692	7.2	37
274	Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors. <i>Immunity</i> , 2016 , 44, 1255-69	32.3	554
273	Unchaining NK cell-mediated anticancer immunosurveillance. <i>Nature Immunology</i> , 2016 , 17, 746-7	19.1	
272	Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials 2016 , 4, 15		47
271	Inhibition of formyl peptide receptor 1 reduces the efficacy of anticancer chemotherapy against carcinogen-induced breast cancer. <i>OncolImmunology</i> , 2016 , 5, e1139275	7.2	17
270	Trial Watch-Immunostimulation with cytokines in cancer therapy. <i>OncolImmunology</i> , 2016 , 5, e1115942	7.2	35
269	Prime time for immune-checkpoint targeted therapy at ASCO 2015. <i>OncolImmunology</i> , 2016 , 5, e1068494	7.2	5
268	The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer. <i>Autophagy</i> , 2016 , 12, 864-75	10.2	75
267	Immunosurveillance in esophageal carcinoma: The decisive impact of regulatory T cells. <i>OncolImmunology</i> , 2016 , 5, e1064581	7.2	11
266	Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis. <i>Journal of Investigative Dermatology</i> , 2016 , 136, 994-1001	4.3	20

265	Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. <i>Immunity</i> , 2016 , 44, 343-54	32.3	518
264	Trial Watch-Oncolytic viruses and cancer therapy. <i>OncolImmunology</i> , 2016 , 5, e1117740	7.2	76
263	Therapy-induced microenvironmental changes in cancer. <i>Journal of Molecular Medicine</i> , 2016 , 94, 497-508	9.5	13
262	Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy. <i>OncolImmunology</i> , 2016 , 5, e1149673	7.2	99
261	Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy. <i>OncolImmunology</i> , 2016 , 5, e1149674	7.2	41
260	Immunogenic cell death-related biomarkers: Impact on the survival of breast cancer patients after adjuvant chemotherapy. <i>OncolImmunology</i> , 2016 , 5, e1082706	7.2	31
259	Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma. <i>Journal of Clinical Investigation</i> , 2016 , 126, 921-37	15.9	48
258	Dendritic cell-derived exosomes for cancer therapy. <i>Journal of Clinical Investigation</i> , 2016 , 126, 1224-32	15.9	267
257	Extracellular vesicles: masters of intercellular communication and potential clinical interventions. <i>Journal of Clinical Investigation</i> , 2016 , 126, 1139-43	15.9	263
256	Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance. <i>Cancer Cell</i> , 2016 , 30, 147-160	24.3	285
255	Immunological off-target effects of imatinib. <i>Nature Reviews Clinical Oncology</i> , 2016 , 13, 431-46	19.4	90
254	Yet another pattern recognition receptor involved in the chemotherapy-induced anticancer immune response: Formyl peptide receptor-1. <i>OncolImmunology</i> , 2016 , 5, e1118600	7.2	14
253	NKp30 isoforms and NKp46 transcripts in metastatic melanoma patients: Unique NKp30 pattern in rare melanoma patients with favorable evolution. <i>OncolImmunology</i> , 2016 , 5, e1154251	7.2	15
252	Biomarkers of immunogenic stress in metastases from melanoma patients: Correlations with the immune infiltrate. <i>OncolImmunology</i> , 2016 , 5, e1160193	7.2	9
251	STAT3 inhibition for cancer therapy: Cell-autonomous effects only?. <i>OncolImmunology</i> , 2016 , 5, e1126063	7.2	10
250	Positive impact of autophagy in human breast cancer cells on local immunosurveillance. <i>OncolImmunology</i> , 2016 , 5, e1174801	7.2	8
249	Microbiome and Anticancer Immunosurveillance. <i>Cell</i> , 2016 , 165, 276-87	56.2	244
248	Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients. <i>Cancer Cell</i> , 2016 , 29, 587-601	24.3	259

247	The oncolytic compound LTX-401 targets the Golgi apparatus. <i>Cell Death and Differentiation</i> , 2016 , 23, 2031-2041	12.7	16
246	Mouse models in oncoimmunology. <i>Nature Reviews Cancer</i> , 2016 , 16, 759-773	31.3	185
245	Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition. <i>OncolImmunology</i> , 2016 , 5, e1220467	7.2	70
244	<i>Enterococcus hirae</i> and <i>Barnesiella intestinihominis</i> Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects. <i>Immunity</i> , 2016 , 45, 931-943	32.3	376
243	A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1. <i>Cancer Research</i> , 2015 , 75, 3800-11	10.1	151
242	CANCER. A p53-regulated immune checkpoint relevant to cancer. <i>Science</i> , 2015 , 349, 476-7	33.3	19
241	STAT3 Inhibition Enhances the Therapeutic Efficacy of Immunogenic Chemotherapy by Stimulating Type 1 Interferon Production by Cancer Cells. <i>Cancer Research</i> , 2015 , 75, 3812-22	10.1	61
240	Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. <i>OncolImmunology</i> , 2015 , 4, e1008814	7.2	68
239	Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. <i>OncolImmunology</i> , 2015 , 4, e1008866	7.2	162
238	Cancer: Antibodies regulate antitumour immunity. <i>Nature</i> , 2015 , 521, 35-7	50.4	26
237	Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients. <i>Science Translational Medicine</i> , 2015 , 7, 283ra55	17.5	97
236	Cancer and the gut microbiota: an unexpected link. <i>Science Translational Medicine</i> , 2015 , 7, 271ps1	17.5	277
235	Immunologic correlates in the course of treatment with immunomodulating antibodies. <i>Seminars in Oncology</i> , 2015 , 42, 448-58	5.5	19
234	Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. <i>Science</i> , 2015 , 350, 1079-84	33.3	1689
233	Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. <i>Science</i> , 2015 , 350, 972-8	33.3	267
232	Natural and therapy-induced immunosurveillance in breast cancer. <i>Nature Medicine</i> , 2015 , 21, 1128-38	50.5	196
231	Subversion of anticancer immunosurveillance by radiotherapy. <i>Nature Immunology</i> , 2015 , 16, 1005-7	19.1	30
230	Natural killer cell mediated immunosurveillance of pediatric neuroblastoma. <i>OncolImmunology</i> , 2015 , 4, e1042202	7.2	22

229	Trial Watch: Adoptive cell transfer for oncological indications. <i>OncolImmunology</i> , 2015 , 4, e1046673	7.2	22
228	Trial watch: Naked and vectored DNA-based anticancer vaccines. <i>OncolImmunology</i> , 2015 , 4, e1026531	7.2	22
227	Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer. <i>Autophagy</i> , 2015 , 11, 1878-90	10.2	78
226	The role of the microbiota in inflammation, carcinogenesis, and cancer therapy. <i>European Journal of Immunology</i> , 2015 , 45, 17-31	6.1	143
225	Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. <i>Frontiers in Immunology</i> , 2015 , 6, 588	8.4	239
224	Characterization of the Microenvironment in Positive and Negative Sentinel Lymph Nodes from Melanoma Patients. <i>PLoS ONE</i> , 2015 , 10, e0133363	3.7	11
223	Type I interferons in anticancer immunity. <i>Nature Reviews Immunology</i> , 2015 , 15, 405-14	36.5	606
222	Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. <i>Cancer Cell</i> , 2015 , 28, 690-714	24.3	828
221	The oncolytic peptide LTX-315 triggers necrotic cell death. <i>Cell Cycle</i> , 2015 , 14, 3506-12	4.7	19
220	Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. <i>OncolImmunology</i> , 2015 , 4, e985940	7.2	38
219	Trial Watch: Peptide-based anticancer vaccines. <i>OncolImmunology</i> , 2015 , 4, e974411	7.2	81
218	Microbiota modulation of myeloid cells in cancer therapy. <i>Cancer Immunology Research</i> , 2015 , 3, 103-9	12.5	28
217	Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. <i>Cell Research</i> , 2015 , 25, 208-24	24.7	126
216	Meta-analysis of organ-specific differences in the structure of the immune infiltrate in major malignancies. <i>Oncotarget</i> , 2015 , 6, 11894-909	3.3	34
215	Negative prognostic impact of regulatory T cell infiltration in surgically resected esophageal cancer post-radiochemotherapy. <i>Oncotarget</i> , 2015 , 6, 20840-50	3.3	41
214	The oncolytic peptide LTX-315 kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilization. <i>Oncotarget</i> , 2015 , 6, 26599-614	3.3	32
213	Autocrine signaling of type 1 interferons in successful anticancer chemotherapy. <i>OncolImmunology</i> , 2015 , 4, e988042	7.2	21
212	CD103+ dendritic cells producing interleukin-12 in anticancer immunosurveillance. <i>Cancer Cell</i> , 2014 , 26, 591-3	24.3	28

211	Trial Watch: Chemotherapy with immunogenic cell death inducers. <i>OncolImmunology</i> , 2014 , 3, e27878	7.2	116
210	Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma. <i>Cancer Research</i> , 2014 , 74, 7298-308	10.1	79
209	Targeting foxp1 for reinstating anticancer immunosurveillance. <i>Immunity</i> , 2014 , 41, 345-347	32.3	3
208	Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. <i>Nature Medicine</i> , 2014 , 20, 1301-9	50.5	596
207	Dendritic cell-derived exosomes as immunotherapies in the fight against cancer. <i>Journal of Immunology</i> , 2014 , 193, 1006-11	5.3	181
206	Trial Watch: Adoptive cell transfer for anticancer immunotherapy. <i>OncolImmunology</i> , 2014 , 3, e28344	7.2	30
205	Cell-death-associated molecular patterns as determinants of cancer immunogenicity. <i>Antioxidants and Redox Signaling</i> , 2014 , 20, 1098-116	8.4	31
204	Cytokines reinstate NK cell-mediated cancer immunosurveillance. <i>Journal of Clinical Investigation</i> , 2014 , 124, 4687-9	15.9	4
203	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014 , 5, 12472-508	3.3	301
202	Consensus guidelines for the detection of immunogenic cell death. <i>OncolImmunology</i> , 2014 , 3, e955691	7.2	524
201	Trial Watch: Toll-like receptor agonists in oncological indications. <i>OncolImmunology</i> , 2014 , 3, e29179	7.2	61
200	Synthetic induction of immunogenic cell death by genetic stimulation of endoplasmic reticulum stress. <i>OncolImmunology</i> , 2014 , 3, e28276	7.2	19
199	Trial Watch: Radioimmunotherapy for oncological indications. <i>OncolImmunology</i> , 2014 , 3, e954929	7.2	36
198	Trial Watch: DNA vaccines for cancer therapy. <i>OncolImmunology</i> , 2014 , 3, e28185	7.2	33
197	Trial watch: IDO inhibitors in cancer therapy. <i>OncolImmunology</i> , 2014 , 3, e957994	7.2	166
196	Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. <i>OncolImmunology</i> , 2014 , 3, e27297	7.2	86
195	Trial Watch:: Oncolytic viruses for cancer therapy. <i>OncolImmunology</i> , 2014 , 3, e28694	7.2	88
194	Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set. <i>OncolImmunology</i> , 2014 , 3, e28473	7.2	83

193	Immune-related gene signatures predict the outcome of neoadjuvant chemotherapy. <i>Oncolimmunology</i> , 2014 , 3, e27884	7.2	61
192	Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors. <i>Oncolimmunology</i> , 2014 , 3, e27560	7.2	34
191	Mature cytotoxic CD56(bright)/CD16(+) natural killer cells can infiltrate lymph nodes adjacent to metastatic melanoma. <i>Cancer Research</i> , 2014 , 74, 81-92	10.1	66
190	Regulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15R α and NKG2D triggering. <i>Cancer Research</i> , 2014 , 74, 68-80	10.1	33
189	Trial watch: Dendritic cell-based anticancer therapy. <i>Oncolimmunology</i> , 2014 , 3, e963424	7.2	54
188	Chemokines and chemokine receptors required for optimal responses to anticancer chemotherapy. <i>Oncolimmunology</i> , 2014 , 3, e27663	7.2	28
187	CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy. <i>Cancer Research</i> , 2014 , 74, 436-45	10.1	90
186	An autophagy-dependent anticancer immune response determines the efficacy of melanoma chemotherapy. <i>Oncolimmunology</i> , 2014 , 3, e944047	7.2	56
185	Why should we need the gut microbiota to respond to cancer therapies?. <i>Oncolimmunology</i> , 2014 , 3, e27574	7.2	14
184	Autophagy and cellular immune responses. <i>Immunity</i> , 2013 , 39, 211-27	32.3	296
183	Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. <i>Cancer Research</i> , 2013 , 73, 3499-510	10.1	215
182	The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. <i>Science</i> , 2013 , 342, 971-6	33.3	1128
181	Lung cancer: potential targets for immunotherapy. <i>Lancet Respiratory Medicine</i> , 2013 , 1, 551-63	35.1	55
180	Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. <i>Immunity</i> , 2013 , 39, 74-88	32.3	609
179	Neutralizing tumor-promoting chronic inflammation: a magic bullet?. <i>Science</i> , 2013 , 339, 286-91	33.3	754
178	Mucosal imprinting of vaccine-induced CD8+ T cells is crucial to inhibit the growth of mucosal tumors. <i>Science Translational Medicine</i> , 2013 , 5, 172ra20	17.5	165
177	Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. <i>Immunity</i> , 2013 , 38, 729-41	32.3	439
176	Immunogenic cell death in cancer therapy. <i>Annual Review of Immunology</i> , 2013 , 31, 51-72	34.7	1757

175	Crosstalk between ER stress and immunogenic cell death. <i>Cytokine and Growth Factor Reviews</i> , 2013 , 24, 311-8	17.9	106
174	Trial watch: DNA vaccines for cancer therapy. <i>Oncolmmunology</i> , 2013 , 2, e23803	7.2	70
173	Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate. <i>Oncolmmunology</i> , 2013 , 2, e23079	7.2	16
172	Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR NK cell levels correlate with disease outcome. <i>Oncolmmunology</i> , 2013 , 2, e23080	7.2	24
171	Potent immunomodulatory effects of the trifunctional antibody catumaxomab. <i>Cancer Research</i> , 2013 , 73, 4663-73	10.1	29
170	An anticancer therapy-elicited immunosurveillance system that eliminates tetraploid cells. <i>Oncolmmunology</i> , 2013 , 2, e22409	7.2	17
169	ATP-dependent recruitment, survival and differentiation of dendritic cell precursors in the tumor bed after anticancer chemotherapy. <i>Oncolmmunology</i> , 2013 , 2, e24568	7.2	61
168	Victories and deceptions in tumor immunology: Stimuvax. <i>Oncolmmunology</i> , 2013 , 2, e23687	7.2	38
167	NCR3/NKp30 contributes to pathogenesis in primary Sjogren's syndrome. <i>Science Translational Medicine</i> , 2013 , 5, 195ra96	17.5	81
166	Trial watch: Cardiac glycosides and cancer therapy. <i>Oncolmmunology</i> , 2013 , 2, e23082	7.2	89
165	Analysis of NKp30/NCR3 isoforms in untreated HIV-1-infected patients from the ANRS SEROCO cohort. <i>Oncolmmunology</i> , 2013 , 2, e23472	7.2	16
164	Immunological effects of chemotherapy in spontaneous breast cancers. <i>Oncolmmunology</i> , 2013 , 2, e27158	7.2	14
163	Following up tumor-specific regulatory T cells in cancer patients. <i>Oncolmmunology</i> , 2013 , 2, e25444	7.2	12
162	Trial watch: Dendritic cell-based interventions for cancer therapy. <i>Oncolmmunology</i> , 2013 , 2, e25771	7.2	87
161	Trial Watch: Lenalidomide-based immunochemotherapy. <i>Oncolmmunology</i> , 2013 , 2, e26494	7.2	39
160	Trial watch: Monoclonal antibodies in cancer therapy. <i>Oncolmmunology</i> , 2013 , 2, e22789	7.2	76
159	Trial watch: Chemotherapy with immunogenic cell death inducers. <i>Oncolmmunology</i> , 2013 , 2, e23510	7.2	72
158	Trial Watch: Peptide vaccines in cancer therapy. <i>Oncolmmunology</i> , 2013 , 2, e26621	7.2	84

157	Trial Watch: Adoptive cell transfer for anticancer immunotherapy. <i>Oncolmunology</i> , 2013 , 2, e24238	7.2	43
156	Trial Watch: Immunostimulatory cytokines. <i>Oncolmunology</i> , 2013 , 2, e24850	7.2	44
155	Tumor necrosis factor is dispensable for the success of immunogenic anticancer chemotherapy. <i>Oncolmunology</i> , 2013 , 2, e24786	7.2	21
154	Trial Watch: Toll-like receptor agonists for cancer therapy. <i>Oncolmunology</i> , 2013 , 2, e25238	7.2	120
153	Trial watch: Oncolytic viruses for cancer therapy. <i>Oncolmunology</i> , 2013 , 2, e24612	7.2	94
152	IKDCs or B220+ NK cells are pre-mNK cells. <i>Blood</i> , 2012 , 119, 4345-6	2.2	11
151	Prognostic impact of vitamin B6 metabolism in lung cancer. <i>Cell Reports</i> , 2012 , 2, 257-69	10.6	100
150	The secret ally: immunostimulation by anticancer drugs. <i>Nature Reviews Drug Discovery</i> , 2012 , 11, 215-336	4.1	494
149	An immunosurveillance mechanism controls cancer cell ploidy. <i>Science</i> , 2012 , 337, 1678-84	33.3	299
148	Trial watch: Dendritic cell-based interventions for cancer therapy. <i>Oncolmunology</i> , 2012 , 1, 1111-1134	7.2	134
147	Trial Watch: Monoclonal antibodies in cancer therapy. <i>Oncolmunology</i> , 2012 , 1, 28-37	7.2	80
146	Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. <i>Oncolmunology</i> , 2012 , 1, 1323-1343	7.2	173
145	Inflammasomes in carcinogenesis and anticancer immune responses. <i>Nature Immunology</i> , 2012 , 13, 343-51	19.1	415
144	Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. <i>Science Translational Medicine</i> , 2012 , 4, 143ra99	17.5	266
143	Cancer-induced immunosuppression: IL-18-elicited immunoablative NK cells. <i>Cancer Research</i> , 2012 , 72, 2757-67	10.1	80
142	Natural killer cells in non-hematopoietic malignancies. <i>Frontiers in Immunology</i> , 2012 , 3, 395	8.4	24
141	Immunohistochemical detection of cytoplasmic LC3 puncta in human cancer specimens. <i>Autophagy</i> , 2012 , 8, 1175-84	10.2	58
140	Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. <i>Oncolmunology</i> , 2012 , 1, 894-907	7.2	163

139	Abscopal but desirable: The contribution of immune responses to the efficacy of radiotherapy. <i>Oncolimmunology</i> , 2012 , 1, 407-408	7.2	48
138	Loss-of-function alleles of P2RX7 and TLR4 fail to affect the response to chemotherapy in non-small cell lung cancer. <i>Oncolimmunology</i> , 2012 , 1, 271-278	7.2	33
137	Can the exome and the immunome converge on the design of efficient cancer vaccines?. <i>Oncolimmunology</i> , 2012 , 1, 579-580	7.2	21
136	Anticancer activity of cardiac glycosides: At the frontier between cell-autonomous and immunological effects. <i>Oncolimmunology</i> , 2012 , 1, 1640-1642	7.2	73
135	Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. <i>Oncolimmunology</i> , 2012 , 1, 326-333	7.2	85
134	The European Academy of Tumor Immunology: Bridging fields, continents and generations. <i>Oncolimmunology</i> , 2012 , 1, 127-128	7.2	
133	Subversion of the chemotherapy-induced anticancer immune response by the ecto-ATPase CD39. <i>Oncolimmunology</i> , 2012 , 1, 393-395	7.2	52
132	Premortem autophagy determines the immunogenicity of chemotherapy-induced cancer cell death. <i>Autophagy</i> , 2012 , 8, 413-5	10.2	74
131	Cutting edge: Fc β III (CD16) and Fc β I (CD64) are responsible for anti-glycoprotein 75 monoclonal antibody TA99 therapy for experimental metastatic B16 melanoma. <i>Journal of Immunology</i> , 2012 , 189, 5513-7	5.3	27
130	Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. <i>Oncolimmunology</i> , 2012 , 1, 699-716	7.2	164
129	Reply to: Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system. <i>Nature Medicine</i> , 2012 , 18, 346-346	50.5	7
128	Targeting PD-1/PD-L1 interactions for cancer immunotherapy. <i>Oncolimmunology</i> , 2012 , 1, 1223-1225	7.2	248
127	Trial Watch: Adoptive cell transfer immunotherapy. <i>Oncolimmunology</i> , 2012 , 1, 306-315	7.2	58
126	Oncolimmunology: a new journal at the frontier between oncology and immunology. <i>Oncolimmunology</i> , 2012 , 1, 1-2	7.2	19
125	Trial Watch: Immunostimulatory cytokines. <i>Oncolimmunology</i> , 2012 , 1, 493-506	7.2	66
124	Homeostatic defects in interleukin 18-deficient mice contribute to protection against the lethal effects of endotoxin. <i>Immunology and Cell Biology</i> , 2011 , 89, 739-46	5	15
123	Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. <i>Science</i> , 2011 , 334, 1573-7	33.3	939
122	Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. <i>Journal of Experimental Medicine</i> , 2011 , 208, 491-503	16.6	261

121	Innate or adaptive immunity? The example of natural killer cells. <i>Science</i> , 2011 , 331, 44-9	33.3	1786
120	Immune parameters affecting the efficacy of chemotherapeutic regimens. <i>Nature Reviews Clinical Oncology</i> , 2011 , 8, 151-60	19.4	490
119	Harnessing dendritic cells in cancer. <i>Seminars in Immunology</i> , 2011 , 23, 42-9	10.7	49
118	How to improve the immunogenicity of chemotherapy and radiotherapy. <i>Cancer and Metastasis Reviews</i> , 2011 , 30, 71-82	9.6	66
117	The ultimate goal of curative anti-cancer therapies: inducing an adaptive anti-tumor immune response. <i>Frontiers in Immunology</i> , 2011 , 2, 66	8.4	7
116	Prerequisites for the antitumor vaccine-like effect of chemotherapy and radiotherapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2011 , 17, 351-8	2.2	66
115	Antibody co-targeting of DCs. <i>Blood</i> , 2011 , 118, 6726-7	2.2	2
114	Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. <i>Nature Medicine</i> , 2011 , 17, 700-7	50.5	244
113	IL-18 induces PD-1-dependent immunosuppression in cancer. <i>Cancer Research</i> , 2011 , 71, 5393-9	10.1	245
112	Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. <i>Cancer and Metastasis Reviews</i> , 2011 , 30, 61-9	9.6	218
111	Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. <i>Seminars in Immunopathology</i> , 2011 , 33, 369-83	12	217
110	TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer. <i>Cancer Research</i> , 2011 , 71, 1607-14	10.1	87
109	The dendritic cell-tumor cross-talk in cancer. <i>Current Opinion in Immunology</i> , 2011 , 23, 146-52	7.8	66
108	An inhibitor of cyclin-dependent kinases suppresses TLR signaling and increases the susceptibility of cancer patients to herpesviridae. <i>Cell Cycle</i> , 2011 , 10, 118-26	4.7	6
107	Cyclophosphamide induces differentiation of Th17 cells in cancer patients. <i>Cancer Research</i> , 2011 , 71, 661-5	10.1	113
106	Cutting edge: crucial role of IL-1 and IL-23 in the innate IL-17 response of peripheral lymph node NK1.1-invariant NKT cells to bacteria. <i>Journal of Immunology</i> , 2011 , 186, 662-6	5.3	123
105	Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. <i>Cancer Research</i> , 2011 , 71, 4809-20	10.1	239
104	The IKK complex contributes to the induction of autophagy. <i>EMBO Journal</i> , 2010 , 29, 619-31	13	248

103	Surface-exposed calreticulin in the interaction between dying cells and phagocytes. <i>Annals of the New York Academy of Sciences</i> , 2010 , 1209, 77-82	6.5	77
102	Desirable cell death during anticancer chemotherapy. <i>Annals of the New York Academy of Sciences</i> , 2010 , 1209, 99-108	6.5	58
101	Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. <i>Journal of Clinical Investigation</i> , 2010 , 120, 457-71	15.9	651
100	Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands. <i>Cancer Research</i> , 2010 , 70, 490-500	10.1	87
99	Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. <i>Clinical Cancer Research</i> , 2010 , 16, 3100-4	12.9	270
98	Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. <i>Cancer Research</i> , 2010 , 70, 855-8	10.1	244
97	In vivo depletion of T lymphocyte-specific transcription factors by RNA interference. <i>Cell Cycle</i> , 2010 , 9, 2902-2907	4.7	5
96	Integration of host-related signatures with cancer cell-derived predictors for the optimal management of anticancer chemotherapy. <i>Cancer Research</i> , 2010 , 70, 9538-43	10.1	24
95	Dendritic cell-derived exosomes for cancer immunotherapy: what's next?. <i>Cancer Research</i> , 2010 , 70, 1281-5	10.1	223
94	NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 708-22	4.7	28
93	Decoding cell death signals in inflammation and immunity. <i>Cell</i> , 2010 , 140, 798-804	56.2	422
92	Chemotherapy and radiotherapy: cryptic anticancer vaccines. <i>Seminars in Immunology</i> , 2010 , 22, 113-24	10.7	164
91	IKK connects autophagy to major stress pathways. <i>Autophagy</i> , 2010 , 6, 189-91	10.2	39
90	Bacterial invasion: linking autophagy and innate immunity. <i>Current Biology</i> , 2010 , 20, R106-8	6.3	11
89	Pyroptosis - a cell death modality of its kind?. <i>European Journal of Immunology</i> , 2010 , 40, 627-30	6.1	109
88	Chemotherapy induces ATP release from tumor cells. <i>Cell Cycle</i> , 2009 , 8, 3723-8	4.7	199
87	Phylogenetic conservation of the preapoptotic calreticulin exposure pathway from yeast to mammals. <i>Cell Cycle</i> , 2009 , 8, 639-42	4.7	20
86	Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. <i>Cancer Research</i> , 2009 , 69, 3563-9	10.1	160

85	Anticancer immunochemotherapy using adjuvants with direct cytotoxic effects. <i>Journal of Clinical Investigation</i> , 2009 , 119, 2127-30	15.9	45
84	Viral subversion of immunogenic cell death. <i>Cell Cycle</i> , 2009 , 8, 860-9	4.7	55
83	The dendritic cell-like functions of IFN-producing killer dendritic cells reside in the CD11b+ subset and are licensed by tumor cells. <i>Cancer Research</i> , 2009 , 69, 6590-7	10.1	25
82	Immunogenic cell death modalities and their impact on cancer treatment. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2009 , 14, 364-75	5.4	163
81	Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. <i>EMBO Journal</i> , 2009 , 28, 578-90	13	539
80	Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. <i>Nature Medicine</i> , 2009 , 15, 1170-8	50.5	1284
79	Immunogenic and tolerogenic cell death. <i>Nature Reviews Immunology</i> , 2009 , 9, 353-63	36.5	779
78	Witch hunt against tumor cells enhanced by dendritic cells. <i>Annals of the New York Academy of Sciences</i> , 2009 , 1174, 51-60	6.5	10
77	Disruption of the PP1/GADD34 complex induces calreticulin exposure. <i>Cell Cycle</i> , 2009 , 8, 3971-7	4.7	30
76	Personalized immunotherapy: a siren myth?. <i>Personalized Medicine</i> , 2009 , 6, 469-473	2.2	
75	The immunogenicity of tumor cell death. <i>Current Opinion in Oncology</i> , 2009 , 21, 71-6	4.2	83
74	Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha. <i>PLoS ONE</i> , 2009 , 4, e4942	3.7	286
73	Natural killer cell-directed therapies: moving from unexpected results to successful strategies. <i>Nature Immunology</i> , 2008 , 9, 486-94	19.1	238
72	Immunological aspects of cancer chemotherapy. <i>Nature Reviews Immunology</i> , 2008 , 8, 59-73	36.5	1072
71	Dendritic cells and innate defense against tumor cells. <i>Cytokine and Growth Factor Reviews</i> , 2008 , 19, 79-92	17.9	46
70	Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. <i>Cancer Research</i> , 2008 , 68, 4026-30	10.1	173
69	The critical role of IL-15 in the antitumor effects mediated by the combination therapy imatinib and IL-2. <i>Journal of Immunology</i> , 2008 , 180, 6477-83	5.3	41
68	Regulatory T cells control dendritic cell/NK cell cross-talk in lymph nodes at the steady state by inhibiting CD4+ self-reactive T cells. <i>Journal of Immunology</i> , 2008 , 180, 4679-86	5.3	74

67	Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab?. <i>Clinical Cancer Research</i> , 2008 , 14, 5242-9	12.9	91
66	The anticancer immune response: indispensable for therapeutic success?. <i>Journal of Clinical Investigation</i> , 2008 , 118, 1991-2001	15.9	450
65	Trans-presentation of IL-15 dictates IFN-producing killer dendritic cells effector functions. <i>Journal of Immunology</i> , 2008 , 180, 7887-97	5.3	45
64	CD4+CD25+ Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer. <i>Journal of Clinical Investigation</i> , 2008 , 118, 3751-61	15.9	52
63	Immunogenic cancer cell death: a key-lock paradigm. <i>Current Opinion in Immunology</i> , 2008 , 20, 504-11	7.8	238
62	Tumor destruction using electrochemotherapy followed by CpG oligodeoxynucleotide injection induces distant tumor responses. <i>Cancer Immunology, Immunotherapy</i> , 2008 , 57, 1291-300	7.4	51
61	Killer dendritic cells: IKDC and the others. <i>Current Opinion in Immunology</i> , 2008 , 20, 558-65	7.8	31
60	IL-18 Elicited Suppressor NK Cells with Immunoregulatory Functions. <i>Blood</i> , 2008 , 112, 106-106	2.2	1
59	Calreticulin exposure dictates the immunogenicity of cancer cell death. <i>Nature Medicine</i> , 2007 , 13, 54-61	50.5	2026
58	Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. <i>Nature Medicine</i> , 2007 , 13, 1050-9	50.5	2207
57	Ecto-calreticulin in immunogenic chemotherapy. <i>Immunological Reviews</i> , 2007 , 220, 22-34	11.3	166
56	The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. <i>Immunological Reviews</i> , 2007 , 220, 47-59	11.3	431
55	Death, danger, and immunity: an infernal trio. <i>Immunological Reviews</i> , 2007 , 220, 5-7	11.3	16
54	Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference. <i>Journal of Molecular Medicine</i> , 2007 , 85, 1069-76	5.5	58
53	Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2007 , 56, 641-8	7.4	944
52	Links between innate and cognate tumor immunity. <i>Current Opinion in Immunology</i> , 2007 , 19, 224-31	7.8	55
51	Therapy-induced tumor immunosurveillance involves IFN-producing killer dendritic cells. <i>Cancer Research</i> , 2007 , 67, 851-3	10.1	29
50	Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from "silent" to immunogenic. <i>Cancer Research</i> , 2007 , 67, 7941-4	10.1	116

49	Interferon-gamma is produced by another player of innate immune responses: the interferon-producing killer dendritic cell (IKDC). <i>Biochimie</i> , 2007 , 89, 872-7	4.6	20
48	Immunogenic chemotherapy: discovery of a critical protein through proteomic analyses of tumor cells. <i>Cancer Genomics and Proteomics</i> , 2007 , 4, 65-70	3.3	11
47	Dendritic cell derived-exosomes: biology and clinical implementations. <i>Journal of Leukocyte Biology</i> , 2006 , 80, 471-8	6.5	103
46	Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. <i>Journal of Immunology</i> , 2006 , 176, 2722-9	5.3	174
45	The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. <i>Immunological Reviews</i> , 2006 , 214, 229-38	11.3	204
44	A novel dendritic cell subset involved in tumor immunosurveillance. <i>Nature Medicine</i> , 2006 , 12, 214-9	50.5	340
43	Cancer despite immunosurveillance: immunoselection and immunosubversion. <i>Nature Reviews Immunology</i> , 2006 , 6, 715-27	36.5	946
42	Apoptosis regulation in tetraploid cancer cells. <i>EMBO Journal</i> , 2006 , 25, 2584-95	13	153
41	Selective resistance of tetraploid cancer cells against DNA damage-induced apoptosis. <i>Annals of the New York Academy of Sciences</i> , 2006 , 1090, 35-49	6.5	43
40	CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. <i>Journal of Experimental Medicine</i> , 2005 , 202, 1075-85	16.6	687
39	The potential of exosomes in immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2005 , 5, 737-47	5.4	40
38	Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. <i>Journal of Experimental Medicine</i> , 2005 , 202, 919-29	16.6	592
37	The dialogue between natural killer cells and dendritic cells. <i>International Congress Series</i> , 2005 , 1285, 169-176		
36	The potential of exosomes in immunotherapy of cancer. <i>Blood Cells, Molecules, and Diseases</i> , 2005 , 35, 111-5	2.1	36
35	IL-2 production by dendritic cells is not critical for the activation of cognate and innate effectors in draining lymph nodes. <i>European Journal of Immunology</i> , 2005 , 35, 2840-50	6.1	12
34	Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. <i>Journal of Experimental Medicine</i> , 2005 , 202, 1691-701	16.6	934
33	BCR/ABL promotes dendritic cell-mediated natural killer cell activation. <i>Cancer Research</i> , 2005 , 65, 6409-17	17.1	35
32	Selective accumulation of mature DC-Lamp+ dendritic cells in tumor sites is associated with efficient T-cell-mediated antitumor response and control of metastatic dissemination in melanoma. <i>Cancer Research</i> , 2004 , 64, 2192-8	10.1	85

31	Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. <i>Journal of Immunology</i> , 2004 , 172, 2137-46	5.3	204
30	Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. <i>Journal of Immunology</i> , 2004 , 172, 2126-36	5.3	357
29	IL-4 confers NK stimulatory capacity to murine dendritic cells: a signaling pathway involving KARAP/DAP12-triggering receptor expressed on myeloid cell 2 molecules. <i>Journal of Immunology</i> , 2004 , 172, 5957-66	5.3	58
28	Exosome-based immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2004 , 53, 234-9	7.4	91
27	Proteomic analysis of exosomes secreted by human mesothelioma cells. <i>American Journal of Pathology</i> , 2004 , 164, 1807-15	5.8	289
26	Immune response against dying tumor cells. <i>Advances in Immunology</i> , 2004 , 84, 131-79	5.6	94
25	Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo. <i>Blood</i> , 2004 , 103, 1966-7; author reply 1967	2.2	41
24	Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. <i>Journal of Clinical Investigation</i> , 2004 , 114, 379-88	15.9	218
23	Exosomes: composition, biogenesis and function. <i>Nature Reviews Immunology</i> , 2002 , 2, 569-79	36.5	3459
22	Antigen presentation and T cell stimulation by dendritic cells. <i>Annual Review of Immunology</i> , 2002 , 20, 621-67	34.7	1362
21	Dendritic and natural killer cells cooperate in the control/switch of innate immunity. <i>Journal of Experimental Medicine</i> , 2002 , 195, F9-14	16.6	215
20	Dendritic cells for NK/LAK activation: rationale for multicellular immunotherapy in neuroblastoma patients. <i>Blood</i> , 2002 , 100, 2554-61	2.2	48
19	Malignant effusions and immunogenic tumour-derived exosomes. <i>Lancet, The</i> , 2002 , 360, 295-305	4.0	722
18	Dendritic cells (DC) promote natural killer (NK) cell functions: dynamics of the human DC/NK cell cross talk. <i>European Cytokine Network</i> , 2002 , 13, 17-27	3.3	53
17	From the antigen-presenting cell to the antigen-presenting vesicle: the exosomes. <i>Current Opinion in Molecular Therapeutics</i> , 2002 , 4, 372-81		19
16	Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. <i>Nature Medicine</i> , 2001 , 7, 297-303	50.5	1145
15	Cross-presentation by dendritic cells of tumor antigen expressed in apoptotic recombinant canarypox virus-infected dendritic cells. <i>Journal of Immunology</i> , 2001 , 167, 1795-802	5.3	64
14	Dendritic cell maturation overrules H-2D-mediated natural killer T (NKT) cell inhibition: critical role for B7 in CD1d-dependent NKT cell interferon gamma production. <i>Journal of Experimental Medicine</i> , 2001 , 194, 1179-86	16.6	66

13	. <i>Annals of Oncology</i> , 2000 , 11, 199-206	10.3	10
12	Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73. <i>Journal of Cell Biology</i> , 1999 , 147, 599-610	7.3	826
11	Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. <i>Nature Medicine</i> , 1999 , 5, 405-11	50.5	893
10	Interleukin-12 gene therapy prevents establishment of SCC VII squamous cell carcinomas, inhibits tumor growth, and elicits long-term antitumor immunity in syngeneic C3H mice. <i>Laryngoscope</i> , 1998 , 108, 261-8	3.6	28
9	Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. <i>Nature Medicine</i> , 1998 , 4, 594-600	50.5	1594
8	Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines. <i>Stem Cells</i> , 1997 , 15, 94-103	5.8	113
7	Murine models of cancer cytokine gene therapy using interleukin-12. <i>Annals of the New York Academy of Sciences</i> , 1996 , 795, 275-83	6.5	32
6	IL-12-engineered dendritic cells serve as effective tumor vaccine adjuvants in vivo. <i>Annals of the New York Academy of Sciences</i> , 1996 , 795, 284-93	6.5	79
5	Cytokine gene therapy of cancer using interleukin-12: murine and clinical trials. <i>Annals of the New York Academy of Sciences</i> , 1996 , 795, 440-54	6.5	62
4	Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. <i>European Journal of Immunology</i> , 1996 , 26, 1335-41	6.1	122
3	IL-12 gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts. <i>Human Gene Therapy</i> , 1995 , 6, 1607-24	4.8	60
2	Construction and characterization of retroviral vectors expressing biologically active human interleukin-12. <i>Human Gene Therapy</i> , 1994 , 5, 1493-506	4.8	117
1	Retroviral vectors for use in human gene therapy for cancer, Gaucher disease, and arthritis. <i>Annals of the New York Academy of Sciences</i> , 1994 , 716, 72-88; discussion 88-9	6.5	34